Candel Therapeutics, Inc. CADL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.32M+88.9% | $30.5M+57.9% | $24.29M+11.6% | $21.24M-4.3% | $19.23M-16.9% | ||
| $20.1M+39.9% | $17.77M+26.4% | $16.37M+18.7% | $14.97M+11.1% | $14.37M+6.3% | ||
| $56.42M+67.9% | $48.27M+44.6% | $40.66M+14.4% | $36.21M+1.6% | $33.6M-8.3% | ||
| -$56.42M-67.9% | -$48.27M-44.6% | -$40.66M-14.4% | -$36.21M-1.6% | -$33.6M+8.3% | ||
| $3.38M+93.0% | $2.12M+1.4% | $1.09M-53.9% | $1.42M-44.5% | $1.75M-33.5% | ||
| —— | —— | $17.9M— | $14.07M— | -$5.98M— | ||
| -$54.42M-37.5% | -$38.18M+30.8% | -$22.76M+56.4% | -$22.14M+55.7% | -$39.58M-5.9% | ||
| -$0.99+25.6% | -$0.72+58.6% | -$0.56+67.6% | -$0.68+59.8% | -$1.33-3.9% | ||
| -$55.71M-70.3% | -$47.46M-46.1% | -$39.77M-14.8% | -$35.32M-1.6% | -$32.71M+8.4% | ||
| -$56.42M-67.9% | -$48.27M-44.6% | -$40.66M-14.4% | -$36.21M-1.6% | -$33.6M+8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Candel Therapeutics, Inc.'s revenue?
- Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
